Rituximab in Primary Lymphocyte Predominant Hodgkin´s Disease(RIPL)
Phase 2
Completed
- Conditions
- Lymphocyte Predominant Hodgkin´s Lymphoma (LPHD)
- Registration Number
- NCT00346684
- Lead Sponsor
- University of Cologne
- Brief Summary
First line therapy for patients with Lymphocyte predominant Hodgkin´s Disease (LPHD) in clinical stage IA using the monoclonal anti-CD20 antibody rituximab
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
- lymphocyte predominant Hodgkin´s lymphoma (histologically proven)
- clinical stage IA (without risk factors: large mediastinal mass, extranodal involvement, ESR > 50mm/h)
- age 18 - 75
- WHO performance status 0-3
- normal organ function
- written informed consent
Exclusion Criteria
- classical Hodgkin´s lymphoma
- composite lymphoma
- leucocytes < 3000/µl
- thrombocytes < 100.000/µl
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
University of Cologne
🇩🇪Cologne, Germany